Jefferies Group Weighs in on Marrone Bio Innovations Inc’s FY2022 Earnings (MBII)

Marrone Bio Innovations Inc (NASDAQ:MBII) – Jefferies Group issued their FY2022 EPS estimates for shares of Marrone Bio Innovations in a report released on Thursday. Jefferies Group analyst L. Alexander expects that the basic materials company will post earnings of $0.03 per share for the year.

Marrone Bio Innovations (NASDAQ:MBII) last announced its earnings results on Monday, November 13th. The basic materials company reported ($0.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.03). The company had revenue of $4.22 million during the quarter, compared to analyst estimates of $5.32 million.

Several other analysts have also recently commented on MBII. ValuEngine upgraded Marrone Bio Innovations from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. HC Wainwright set a $4.00 target price on Marrone Bio Innovations and gave the company a “buy” rating in a report on Thursday, December 21st. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $2.50.

Shares of Marrone Bio Innovations (NASDAQ:MBII) traded up $0.06 during mid-day trading on Friday, reaching $1.24. The company had a trading volume of 145,525 shares, compared to its average volume of 102,608. Marrone Bio Innovations has a 1-year low of $0.85 and a 1-year high of $2.30. The company has a market capitalization of $36.99, a PE ratio of -1.03 and a beta of 0.26. The company has a debt-to-equity ratio of -1.14, a current ratio of 0.69 and a quick ratio of 0.36.

An institutional investor recently raised its position in Marrone Bio Innovations stock. Ardsley Advisory Partners grew its holdings in shares of Marrone Bio Innovations Inc (NASDAQ:MBII) by 375.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,681,580 shares of the basic materials company’s stock after buying an additional 2,907,142 shares during the period. Ardsley Advisory Partners owned approximately 11.74% of Marrone Bio Innovations worth $4,528,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 37.59% of the company’s stock.

In other Marrone Bio Innovations news, insider Ardsley Advisory Partners purchased 6,666,667 shares of the business’s stock in a transaction on Monday, February 5th. The shares were purchased at an average cost of $0.75 per share, for a total transaction of $5,000,000.25. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 2.80% of the stock is currently owned by corporate insiders.

WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at

Marrone Bio Innovations Company Profile

Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.

Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with's FREE daily email newsletter.

Leave a Reply